Literature DB >> 21571959

Von Willebrand factor assay proficiency testing. The North American Specialized Coagulation Laboratory Association experience.

Wayne L Chandler1, Ellinor I B Peerschke, Donna D Castellone, Piet Meijer.   

Abstract

We evaluated the accuracy and precision of von Willebrand disease (vWD) testing performed by up to 50 North American Specialty Coagulation Laboratories from 2004 through 2009, using proficiency samples from healthy subjects (n = 7) and patients with type 1 vWD (n = 7) or type 2 vWD (n = 3). We analyzed 2,212 submitted results. Precision was highest for von Willebrand factor (vWF) antigen assays (coefficient of variation, 14%), which were performed predominantly by latex immunoassays, and lowest for ristocetin cofactor assays (coefficient of variation, 28%), which were increasingly replaced by collagen binding and immunofunctional methods during the 6-year evaluation period. Overall interpretation error rates ranged from 3% for normal samples, 28% for type 1 vWD, and 60% for type 2 vWD. Type 2 vWD samples were correctly identified by all laboratories using collagen binding/antigen ratios but by only one third of laboratories using ristocetin cofactor/antigen or immunofunctional/antigen ratios. In 2009, only 27% (12/45) of laboratories performed vWF multimer analysis, with error rates ranging from 7% to 22%.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21571959     DOI: 10.1309/AJCPH5JK4ONENPAE

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  14 in total

1.  Translational medicine advances in von Willebrand disease.

Authors:  D Lillicrap
Journal:  J Thromb Haemost       Date:  2013-06       Impact factor: 5.824

2.  Rapid discrimination of the phenotypic variants of von Willebrand disease.

Authors:  Jonathan C Roberts; Patti A Morateck; Pamela A Christopherson; Ke Yan; Raymond G Hoffmann; Joan Cox Gill; Robert R Montgomery
Journal:  Blood       Date:  2016-02-25       Impact factor: 22.113

Review 3.  Laboratory aspects of von Willebrand disease: test repertoire and options for activity assays and genetic analysis.

Authors:  G Castaman; A Hillarp; A Goodeve
Journal:  Haemophilia       Date:  2014-05       Impact factor: 4.287

4.  Misfolding of vWF to pathologically disordered conformations impacts the severity of von Willebrand disease.

Authors:  Alexander Tischer; Pranathi Madde; Laurie Moon-Tasson; Matthew Auton
Journal:  Biophys J       Date:  2014-09-02       Impact factor: 4.033

5.  Indexes of von Willebrand factor as biomarkers of aortic stenosis severity (from the Biomarkers of Aortic Stenosis Severity [BASS] study).

Authors:  Joseph L Blackshear; Ewa M Wysokinska; Robert E Safford; Colleen S Thomas; Mark E Stark; Brian P Shapiro; Steven Ung; Gretchen S Johns; Dong Chen
Journal:  Am J Cardiol       Date:  2012-11-17       Impact factor: 2.778

6.  Clinical measurement of von Willebrand factor by fluorescence correlation spectroscopy.

Authors:  Richard Torres; Jonathan R Genzen; Michael J Levene
Journal:  Clin Chem       Date:  2012-03-26       Impact factor: 8.327

7.  Preclinical evaluation of a semi-automated and rapid commercial electrophoresis assay for von Willebrand factor multimers.

Authors:  Marika Pikta; Galina Zemtsovskaja; Hector Bautista; Georges Nouadje; Timea Szanto; Margus Viigimaa; Valdas Banys
Journal:  J Clin Lab Anal       Date:  2018-02-17       Impact factor: 2.352

Review 8.  The molecular characterization of von Willebrand disease: good in parts.

Authors:  P D James; D Lillicrap
Journal:  Br J Haematol       Date:  2013-02-14       Impact factor: 6.998

Review 9.  New developments in von Willebrand disease.

Authors:  Helen Fogarty; Dearbhla Doherty; James S O'Donnell
Journal:  Br J Haematol       Date:  2020-05-12       Impact factor: 6.998

10.  Establishment and characterization of a new and stable collagen-binding assay for the assessment of von Willebrand factor activity.

Authors:  Y Ni; J Nesrallah; M Agnew; F J Geske; E J Favaloro
Journal:  Int J Lab Hematol       Date:  2012-10-29       Impact factor: 2.877

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.